These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26032112)

  • 1. Interleukin-1 blockade in neuro-Behçet's disease: a case-based reflection.
    Vitale A; Rigante D; Caso F; Franceschini R; Cantarini L
    Int J Rheum Dis; 2017 Aug; 20(8):1046-1049. PubMed ID: 26032112
    [No Abstract]   [Full Text] [Related]  

  • 2. Anakinra for resistant Behçet uveitis: why not?
    Emmi G; Silvestri E; Cameli AM; Bacherini D; Vannozzi L; Squatrito D; Emmi L
    Clin Exp Rheumatol; 2013; 31(3 Suppl 77):152-3. PubMed ID: 24064028
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: anti-IL1 blocking agents in drug-resistant Behçet's syndrome: our little case series.
    Emmi G; Silvestri E; Ciucciarelli L; Squatrito D; Emmi L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S172. PubMed ID: 24709082
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of anakinra in refractory Behçet's disease sacroiliitis.
    Caso F; Rigante D; Vitale A; Lucherini OM; Cantarini L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S171. PubMed ID: 24709061
    [No Abstract]   [Full Text] [Related]  

  • 5. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value and complications of immunosuppressive therapy in uveitis of Behcet's disease or of other etiology. Apropos of 40 cases].
    Niessen F; Campinchi R; Bloch-Michel E
    J Fr Ophtalmol; 1982; 5(6-7):407-16. PubMed ID: 7130629
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.
    Cantarini L; Lopalco G; Caso F; Costa L; Iannone F; Lapadula G; Anelli MG; Franceschini R; Menicacci C; Galeazzi M; Selmi C; Rigante D
    Autoimmun Rev; 2015 Jan; 14(1):1-9. PubMed ID: 25151975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
    Rosenbaum JT
    J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful use of canakinumab in a patient with resistant Behçet's disease.
    Cantarini L; Vitale A; Borri M; Galeazzi M; Franceschini R
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S115. PubMed ID: 22776542
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.
    Emmi G; Silvestri E; Squatrito D; Vitale A; Bacherini D; Vannozzi L; Emmi L; D'Elios MM; Cantarini L; Prisco D
    Int J Dermatol; 2017 Feb; 56(2):218-220. PubMed ID: 27336860
    [No Abstract]   [Full Text] [Related]  

  • 15. Whole thoracal spinal cord involvement in case of neuro-Behçet's disease.
    Kabukçu T; Edemci S; Uçan H; Celik C; Gunes HN; Yoldas T
    Rheumatol Int; 2009 Apr; 29(6):707-9. PubMed ID: 18982328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myalgia in Neuro-Behçet's disease. Medication side effects or expression of underlying disease].
    Krämer M; Baumgärtel MW; Neuen-Jacob E; Berlit P
    Z Rheumatol; 2008 May; 67(3):232-6. PubMed ID: 18365217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
    Lee RW; Dick AD
    Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
    [No Abstract]   [Full Text] [Related]  

  • 19. A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.
    Chen J; Chen S; He J
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):116-118. PubMed ID: 28980896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases.
    Shugaiv E; Tüzün E; Mutlu M; Kiyat-Atamer A; Kurtuncu M; Akman-Demir G
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S64-7. PubMed ID: 21968239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.